TerminatedNot Applicable

Zinc Sulfate for Human Papillomavirus (HPV)

Stopped: Lack of recruitment

United States21 participantsStarted 2017-10-24

Plain-language summary

The Human Papillomavirus (HPV) is well established as the primary causative agent in both warts and cervical cancer. Although cervical high risk HPV (hrHPV) infections have a high rate of spontaneous resolution this takes time and the infection can cause cervical cells to progress to precancerous and cancerous lesions. Zinc has been shown to play a central role in immunity. This study is to determine if oral zinc sulfate can improve clearance rates of high risk HPV versus placebo.

Who can participate

Age range21 Years – 65 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Abnormal cytology of atypical squamous cells of undetermined significance (ASCUS) on Pap smear OR * Low-grade squamous intra epithelial lesions (LSIL) on Pap smear OR * Positive hrHPV on routine screening (positive HPV will be assumed to be high grade) Exclusion Criteria: * Patients who proceed to excisional procedures (loop electrosurgical excision procedure or cold knife conization) * Pregnant patients * Breastfeeding patients * Immunocompromised patients

What they're measuring

Clearance rates of high risk HPV

Timeframe: During 3 month treatment period

Trial details

NCT IDNCT03404310

SponsorCorewell Health West

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-06-28

View on ClinicalTrials.gov More Human Papilloma Virus trials